LLY Jul 2024 810.000 put
- Investor's Business Daily
Dow Jones Futures: Apple AI Push, Tesla, Fed Loom For Stock Market
The stock market is at highs with Apple's AI push, the Fed rate "dot-plot" and the Tesla shareholder meeting headlining key events and news.
- PR Newswire
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. The efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology
- Investor's Business Daily
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Eli Lilly stock is climbing higher ahead of an FDA meeting to discuss its Alzheimer's treatment. Is LLY stock a buy right now?
